Biocytogen Closes $60 Million Hong Kong IPO for Animal Models and Drug Development
publication date: Sep 1, 2022
Beijing Biocytogen Pharma completed a $60 million IPO on the Hong Kong Exchange for its genetically modified animal and cell model business, which it offers to global pharmaceutical/biotech companies. Using its animal models, Biocytogen has also developed an innovative in vivo drug efficacy and safety screening process to discover 10+ preclinical and clinical candidates, a collection of monoclonal antibodies, bispecific antibodies and bispecific ADCs. Three products have been out-licensed and/or entered co-development. Biocytogen has a market capitalization of $357 million. More details....
Stock Symbol: (HK: 02315)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.